RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort

Cancer Res Treat 47(2):215-220 · 2015 · PMID 25345461

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

207편 검색→189편 판독→93편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Prevalence and progression of monoclonal gammopathy of undetermined significance in older adults Prevalence and progression of monoclonal gammopathy of undetermined significance in older adults

출판 연도

1993: 1편119931994: 1편11995: 1편11997: 1편120002002: 3편32003: 2편22004: 1편12005: 3편320052006: 2편22007: 2편22008: 3편32009: 5편52010: 3편320102012: 3편32013: 4편42014: 3편32015: 5편520152016: 1편12017: 8편82018: 5편52019: 4편42020: 4편420202021: 5편52022: 2편22023: 1편12024: 3편32025: 7편72026: 10편102026

선별된 93편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01follow-up · population-based37편

  1. 0.94

    A long-term study of prognosis in monoclonal gammopathy of undetermined significance

    Kyle RA, Therneau TM, Rajkumar SV et al. · The New England journal of medicine · 2002

  2. 0.93

    Monoclonal gammopathy in Iceland: a population-based registry and follow-up

    Ogmundsdottir HM, Haraldsdottir V, M Johannesson G et al. · British journal of haematology · 2002

  3. 0.93

    Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece

    Anagnostopoulos A, Evangelopoulou A, Sotou D et al. · Annals of hematology · 2002

  4. 0.93

    Monoclonal gammopathy of undetermined significance

    Kyle RA · Blood reviews · 1994

  5. 0.92

    Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France)

    Cabrera Q, Macro M, Hebert B et al. · Cancer epidemiology · 2014

  6. 0.91

    Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance

    Kyle RA, Rajkumar SV, Therneau TM et al. · Clinical lymphoma · 2005

  7. 0.88

    A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

    Sandecka V, Hajek R, Pour L et al. · European journal of haematology · 2017

  8. 0.88

    Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

    Visram A, Larson D, Norman A et al. · Blood · 2025

  9. 0.87

    Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

    El-Khoury H, Lee DJ, Alberge JB et al. · The Lancet. Haematology · 2022

  10. 0.87

    The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions

    Atkin C, Reddy-Kolanu V, Drayson MT et al. · British journal of haematology · 2020

  11. 0.86

    A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea

    Kang KW, Song JE, Lee BH et al. · Scientific reports · 2021

  12. 0.86

    IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom's macroglobulinemia

    Kyle RA, Benson J, Larson D et al. · Clinical lymphoma & myeloma · 2009

  13. 0.85

    Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study

    Roman E, Bagguley T, Crouch S et al. · Haematologica · 2026

  14. 0.84

    Long-term follow-up of IgM monoclonal gammopathy of undetermined significance

    Kyle RA, Therneau TM, Rajkumar SV et al. · Blood · 2003

  15. 0.84

    Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden

    Rognvaldsson S, Thorsteinsdottir S, Syriopoulou E et al. · Haematologica · 2024

  16. 0.84

    The clinical features and prognosis of the monoclonal gammopathy undetermined significance: A single center study

    Ma L, Xu S, Wen L et al. · Blood cells, molecules & diseases · 2018

  17. 0.83

    Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study

    Gupta R, Dahiya M, Kumar L et al. · Clinical lymphoma, myeloma & leukemia · 2018

  18. 0.81

    Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana

    Landgren O, Katzmann JA, Hsing AW et al. · Mayo Clinic proceedings · 2007

  19. 0.80

    Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance

    Pasqualetti P, Casale R · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1997

  20. 0.79

    Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type

    Voigtlaender M, Vogler B, Trepel M et al. · Annals of hematology · 2015

  21. 0.79

    Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system

    Baldini L, Goldaniga M, Guffanti A et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2005

  22. 0.78

    Dietary intake is associated with risk of multiple myeloma and its precursor disease

    Thordardottir M, Lindqvist EK, Lund SH et al. · PloS one · 2018

  23. 0.78

    Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients

    Varettoni M, Corso A, Cocito F et al. · Medicine · 2010

  24. 0.75

    Fracture risk in monoclonal gammopathy of undetermined significance

    Melton LJ3, Rajkumar SV, Khosla S et al. · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2004

  25. 0.74

    Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?

    Steiner N, Schwarzler A, Gobel G et al. · Oncotarget · 2017

  26. 0.71

    Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study

    Lee JY, Jung EJ, Kwon S et al. · Haematologica · 2026

  27. 0.68

    Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up

    Rognvaldsson S, Thorsteinsdottir S, Eythorsson E et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026

  28. 0.68

    Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study

    Rognvaldsson S, Aspelund T, Thorsteinsdottir S et al. · European journal of haematology · 2021

  29. 0.67

    Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

    Jonsdottir AH, Sigurjonsdottir HA, Thorsteinsdottir S et al. · Blood · 2025

  30. 0.62

    Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial

    Eythorsson E, Rognvaldsson S, Thorsteinsdottir S et al. · Annals of internal medicine · 2024

  31. 0.60

    Monoclonal gammopathy of undetermined significance

    Kyle RA, Rajkumar SV · Clinical lymphoma & myeloma · 2005

  32. 0.54

    Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis

    Go RS, Gundrum JD, Neuner JM · Clinical lymphoma, myeloma & leukemia · 2015

  33. 0.54

    Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients

    Jou E, Gligich O, Chan ACY et al. · Hematological oncology · 2017

  34. 0.54

    Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide for osteoporosis: a bicenter retrospective study and analysis of the French national pharmacovigilance database

    Cassez R, Cortet B, Bouvard B et al. · Archives of osteoporosis · 2026

  35. 0.52

    Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients

    Za T, De Stefano V, Rossi E et al. · British journal of haematology · 2013

  36. 0.52

    Multimorbidity in patients with monoclonal gammopathy of undetermined significance

    Epstein MM, Zhou Y, Castaneda-Avila MA et al. · International journal of cancer · 2023

  37. 0.50

    Identifying monoclonal gammopathy of undetermined significance in electronic health data

    Epstein MM, Saphirak C, Zhou Y et al. · Pharmacoepidemiology and drug safety · 2020

02survival · confidence interval19편

  1. 0.93

    Long-term follow-up of a population based cohort with monoclonal proteinaemia

    Schaar CG, le Cessie S, Snijder S et al. · British journal of haematology · 2009

  2. 0.90

    Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

    Landgren O, Gridley G, Turesson I et al. · Blood · 2006

  3. 0.84

    Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

    Dhodapkar MV, Sexton R, Hoering A et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

  4. 0.81

    Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study

    Chang SH, Luo S, Thomas TS et al. · Journal of the National Cancer Institute · 2017

  5. 0.81

    Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population

    Wang M, Sigel B, Liu L et al. · International journal of cancer · 2026

  6. 0.80

    Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma

    Liu L, Sigel B, Wang M et al. · Blood cancer journal · 2026

  7. 0.79

    Cumulative Excess Body Mass Index and MGUS Progression to Myeloma

    Liu L, Grandhi N, Wang M et al. · JAMA network open · 2025

  8. 0.78

    Quantitative risk of underlying disease conditions for progression from monoclonal gammopathy to multiple myeloma: a nationwide cohort study

    Ko H, Choi S, Park SS et al. · ESMO open · 2025

  9. 0.78

    Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

    Landgren O, Kyle RA, Pfeiffer RM et al. · Blood · 2009

  10. 0.75

    Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study

    Chang SH, Luo S, O'Brian KK et al. · The Lancet. Haematology · 2015

  11. 0.75

    Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

    Zuern K, Hielscher T, Werly A et al. · Blood cancer journal · 2024

  12. 0.75

    Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients

    Visram A, Soof C, Rajkumar SV et al. · Blood cancer journal · 2021

  13. 0.72

    Prognostic factors in monoclonal gammopathy of undetermined significance

    Sackmann F, Pavlovsky MA, Corrado C et al. · Haematologica · 2008

  14. 0.66

    Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit

    Bumma N, Nagasaka M, Hemingway G et al. · Clinical lymphoma, myeloma & leukemia · 2020

  15. 0.61

    GLP-1 receptor agonists in patients with MGUS: A real-world propensity-matched study

    Tentolouris A, Ntanasis-Stathopoulos I, Filippatos C et al. · European journal of clinical investigation · 2026

  16. 0.59

    Association and Prognostic Significance of Comorbidities in Individuals With MGUS

    Bawek S, Nassour N, Alharbi M et al. · Clinical lymphoma, myeloma & leukemia · 2026

  17. 0.57

    Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

    Hanamura I, Stewart JP, Huang Y et al. · Blood · 2006

  18. 0.54

    Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma

    Kristinsson SY, Fears TR, Gridley G et al. · Blood · 2008

  19. 0.52

    6q deletion in Waldenstrom macroglobulinaemia negatively affects time to transformation and survival

    Garcia-Sanz R, Dogliotti I, Zaccaria GM et al. · British journal of haematology · 2021

03free light · chain13편

  1. 0.94

    Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

    Kyle RA, Larson DR, Therneau TM et al. · The New England journal of medicine · 2018

  2. 0.93

    Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany

    Eisele L, Durig J, Huttmann A et al. · Annals of hematology · 2012

  3. 0.92

    Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

    Dispenzieri A, Katzmann JA, Kyle RA et al. · Lancet (London, England) · 2010

  4. 0.89

    Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis

    Pelzer BW, Arendt M, Moebus S et al. · Annals of hematology · 2018

  5. 0.89

    New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    Einarsson Long T, Rognvaldsson S, Thorsteinsdottir S et al. · JAMA oncology · 2025

  6. 0.88

    Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age

    Cherry BM, Costello R, Zingone A et al. · American journal of hematology · 2013

  7. 0.85

    Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

    Landgren O, Hofmann JN, McShane CM et al. · JAMA oncology · 2019

  8. 0.83

    Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis

    Maeng CV, Rognvaldsson S, Einarsson Long T et al. · Blood cancer journal · 2025

  9. 0.83

    Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

    Katzmann JA, Clark R, Kyle RA et al. · Leukemia · 2013

  10. 0.78

    Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification

    Andersen LS, Maeng CV, Rognvaldsson S et al. · Blood cancer journal · 2026

  11. 0.59

    Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature

    de Fost M, Out TA, de Wilde FA et al. · Annals of hematology · 2008

  12. 0.52

    Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression

    Andrade-Campos M, Murillo-Florez I, Garcia-Sanz R et al. · Clinical chemistry and laboratory medicine · 2017

  13. 0.50

    The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies

    Greil C, Ihorst G, Gaiser F et al. · European journal of haematology · 2017

04detected · plasma cell10편

  1. 0.95

    Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition

    Therneau TM, Kyle RA, Melton LJ3 et al. · Mayo Clinic proceedings · 2012

  2. 0.89

    Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey

    Landgren O, Graubard BI, Katzmann JA et al. · Leukemia · 2014

  3. 0.89

    Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma

    Neriishi K, Nakashima E, Suzuki G · British journal of haematology · 2003

  4. 0.85

    A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenstrom macroglobulinaemia or other lymphoproliferative disorders

    Varettoni M, Zibellini S, Boveri E et al. · British journal of haematology · 2019

  5. 0.84

    Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors

    Iwanaga M, Tagawa M, Tsukasaki K et al. · Blood · 2009

  6. 0.75

    Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

    Clay-Gilmour AI, Kumar S, Rajkumar SV et al. · Leukemia · 2019

  7. 0.68

    Monoclonal gammopathy in atomic bomb survivors

    Neriishi K, Yoshimoto Y, Carter RL et al. · Radiation research · 1993

  8. 0.64

    Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms

    Varettoni M, Arcaini L, Zibellini S et al. · Blood · 2013

  9. 0.56

    The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

    Ross FM, Chiecchio L, Dagrada G et al. · Haematologica · 2010

  10. 0.55

    The incidence and epidemiology of plasma cell neoplasms

    Bergsagel D · Stem cells (Dayton, Ohio) · 1995

05transplantation · kidney6편

  1. 0.83

    Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

    Kuwabara C, Sakuma Y, Kume A et al. · International journal of hematology · 2019

  2. 0.73

    Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience

    Alfano G, Fontana F, Colaci E et al. · Transplantation · 2017

  3. 0.70

    Outcomes of Monoclonal Gammopathy of Undetermined Significance in Patients Who Underwent Kidney Transplantation

    Bancu I, Canas L, Juega FJ et al. · Transplantation proceedings · 2015

  4. 0.65

    Follow-up monoclonal gammopathy of undetermined significance in kidney transplant

    Cuellar-Garcia C, Sevillano Ruiz-Mateos C, Mazuecos Blanca MA et al. · Transplantation proceedings · 2015

  5. 0.62

    Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation

    Naina HVK, Harris S, Dispenzieri A et al. · American journal of nephrology · 2012

  6. 0.58

    Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance

    Aslam N, Trautman CL, Sher T · Transplantation direct · 2021

06expression · bone marrow6편

  1. 0.81

    Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance

    Castaneda-Avila MA, Lapane KL, Person SD et al. · Hematological oncology · 2022

  2. 0.77

    Association between systemic immune-inflammatory markers and monoclonal gammopathy of undetermined significance in the elderly population: findings from the National health and nutrition examination survey

    Zhang C, Hou K, Lin D et al. · Clinical and experimental medicine · 2026

  3. 0.76

    Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance

    Jerez A, Ortuno FJ, Osma MDM et al. · Annals of medicine · 2009

  4. 0.60

    Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease

    Hofmann JN, Mailankody S, Korde N et al. · Obesity (Silver Spring, Md.) · 2017

  5. 0.59

    Prediagnostic Serum Immune Marker Levels and Multiple Myeloma: A Prospective Longitudinal Study Using Samples from the Janus Serum Bank in Norway

    Herdenberg S, Wibom C, Krop EJM et al. · Cancer prevention research (Philadelphia, Pa.) · 2025

  6. 0.53

    Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders

    Stella F, Pedrazzini E, Baialardo E et al. · Blood cells, molecules & diseases · 2014

07response · syndrome2편

  1. 0.85

    Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size

    Rosinol L, Cibeira MT, Montoto S et al. · Mayo Clinic proceedings · 2007

  2. 0.72

    Clinical characteristics and outcomes in biclonal gammopathies

    Mullikin TC, Rajkumar SV, Dispenzieri A et al. · American journal of hematology · 2016